Lymphocyte subsets in urologic cancer patients

Area of Science:

• Immunology
• Oncology
• Urology

Background:

• T lymphocyte subsets play a crucial role in immune response.
• Alterations in T-cell subsets are observed in various malignancies.
• The impact of cancer and its treatment on T-cell dynamics requires further investigation.

Purpose of the Study:

• To quantify peripheral blood T lymphocyte subsets in patients with urologic malignancies.
• To assess the effects of cancer stage and androgen depletion therapy on T-cell subsets.
• To evaluate the impact of surgical intervention on T-cell parameters.

Main Methods:

• Monoclonal antibodies were used to quantitate T lymphocyte subsets in 91 urologic malignancy patients and 8 controls.
• Flow cytometry was employed for cell subset analysis.
• Patients receiving androgen depletion therapy and surgical treatment were specifically analyzed.

Main Results:

• Urologic malignancies were associated with a relative decrease in helper T-cells and an increase in suppressor T-cells, lowering the T4/T8 ratio.
• Androgen depletion therapy reversed these T-cell subset alterations, normalizing helper and suppressor levels and the T4/T8 ratio.
• Surgery showed only modest immediate and long-term effects on T-cell parameters in a small patient subset.

Conclusions:

• T-cell subset imbalance is linked to urologic malignancies and disease progression.
• Androgen depletion therapy effectively modulates T-cell immunity in these patients.
• Surgical treatment has a limited impact on T-cell subset profiles compared to hormonal therapy.